388 related articles for article (PubMed ID: 23511791)
1. Novel chemotherapies in development for management of castration-resistant prostate cancer.
Tewari AK; George DJ
Curr Opin Urol; 2013 May; 23(3):220-9. PubMed ID: 23511791
[TBL] [Abstract][Full Text] [Related]
2. Androgen annihilation as a new therapeutic paradigm in advanced prostate cancer.
Rove KO; Crawford ED
Curr Opin Urol; 2013 May; 23(3):208-13. PubMed ID: 23492838
[TBL] [Abstract][Full Text] [Related]
3. Overcoming castration resistance in prostate cancer.
Tsao CK; Small AC; Galsky MD; Oh WK
Curr Opin Urol; 2012 May; 22(3):167-74. PubMed ID: 22472508
[TBL] [Abstract][Full Text] [Related]
4. Emerging therapies in metastatic castration-sensitive and castration-resistant prostate cancer.
MacVicar GR; Hussain MH
Curr Opin Oncol; 2013 May; 25(3):252-60. PubMed ID: 23511665
[TBL] [Abstract][Full Text] [Related]
5. Novel agents for the management of castration-resistant prostate cancer.
Haddad H; Garcia JA
Curr Opin Urol; 2012 May; 22(3):175-82. PubMed ID: 22472509
[TBL] [Abstract][Full Text] [Related]
6. Lessons from in-vivo models of castration-resistant prostate cancer.
Lin D; Gout PW; Wang Y
Curr Opin Urol; 2013 May; 23(3):214-9. PubMed ID: 23385975
[TBL] [Abstract][Full Text] [Related]
7. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
[TBL] [Abstract][Full Text] [Related]
8. Novel strategies in the treatment of castration-resistant prostate cancer (Review).
Marech I; Vacca A; Ranieri G; Gnoni A; Dammacco F
Int J Oncol; 2012 May; 40(5):1313-20. PubMed ID: 22322981
[TBL] [Abstract][Full Text] [Related]
9. New therapies for castration-resistant prostate cancer: efficacy and safety.
Beltran H; Beer TM; Carducci MA; de Bono J; Gleave M; Hussain M; Kelly WK; Saad F; Sternberg C; Tagawa ST; Tannock IF
Eur Urol; 2011 Aug; 60(2):279-90. PubMed ID: 21592649
[TBL] [Abstract][Full Text] [Related]
10. The role of IMiDs alone or in combination in prostate cancer.
Nabhan C; Petrylak DP
Clin Genitourin Cancer; 2012 Sep; 10(3):141-6. PubMed ID: 22608152
[TBL] [Abstract][Full Text] [Related]
11. New agents and strategies for the hormonal treatment of castration-resistant prostate cancer.
Sharifi N
Expert Opin Investig Drugs; 2010 Jul; 19(7):837-46. PubMed ID: 20524793
[TBL] [Abstract][Full Text] [Related]
12. Taxane- and epothilone-based chemotherapy: from molecule cargo cytoskeletal logistics to management of castration-resistant prostate carcinoma.
Alberti C
Eur Rev Med Pharmacol Sci; 2013 Jun; 17(12):1658-64. PubMed ID: 23832735
[TBL] [Abstract][Full Text] [Related]
13. Progress in the treatment of advanced prostate cancer.
Sternberg CN; Petrylak DP; Madan RA; Parker C
Am Soc Clin Oncol Educ Book; 2014; ():117-31. PubMed ID: 24857068
[TBL] [Abstract][Full Text] [Related]
14. Epothilones in prostate cancer.
Kelly WK
Urol Oncol; 2011; 29(4):358-65. PubMed ID: 19914096
[TBL] [Abstract][Full Text] [Related]
15. [Somatostatin analogs in the combined treatment of patients with hormone-resistant prostate cancer].
Kaprin AD; Gafanov PA; Fastovets SV
Vopr Onkol; 2009; 55(4):474-6. PubMed ID: 19947374
[No Abstract] [Full Text] [Related]
16. Tubulin-targeted agents including docetaxel and cabazitaxel.
Cheetham P; Petrylak DP
Cancer J; 2013; 19(1):59-65. PubMed ID: 23337758
[TBL] [Abstract][Full Text] [Related]
17. Exploitation of the Androgen Receptor to Overcome Taxane Resistance in Advanced Prostate Cancer.
Martin SK; Kyprianou N
Adv Cancer Res; 2015; 127():123-58. PubMed ID: 26093899
[TBL] [Abstract][Full Text] [Related]
18. [New perspectives in the drug therapy of hormone-resistant prostate cancer].
Vorob'ev NA; Nosov AK; Vorob'ev AV; Moiseenko VM
Vopr Onkol; 2010; 56(6):645-53. PubMed ID: 21395118
[No Abstract] [Full Text] [Related]
19. [New drugs in metastatic castration-resistant prostate cancer].
Albiges L; Loriot Y; Gross-Goupil M; de La Motte Rouge T; Blesius A; Escudier B; Massard C; Fizazi K
Bull Cancer; 2010 Jan; 97(1):149-59. PubMed ID: 20022854
[TBL] [Abstract][Full Text] [Related]
20. Current and emerging treatment modalities for metastatic castration-resistant prostate cancer.
Bracarda S; Logothetis C; Sternberg CN; Oudard S
BJU Int; 2011 Apr; 107 Suppl 2():13-20. PubMed ID: 21382150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
